
## Achievable standards\* for the timing of key events in the MS care pathway




### **Referral and diagnosis**





#### **Priorities following diagnosis**







## **Routine monitoring and support**

Follow-up clinical evaluation
 Review of treatment aims with patient
 Review of eligibility to receive a DMT
 Review of currently prescribed DMT and consideration of alternatives
 Active, documented discussion about living a brain-healthy lifestyle
 Check-up to screen for and/or manage comorbidities

Every 1 year

Offer of an MRI scan





#### **Treatment decisions**

Patient becomes eligible for a DMT

3 weeks

Patient offered appropriate DMT

Patient agrees to start DMT

2 weeks

Treatment with DMT commences





## **Managing new symptoms**





# **Expert consensus on standards for timely MS care**

Expert consensus on standards for timely his care				
	Core	Achievable	Aspirational	Reporting first symptoms
Referral and diagnosis	4 weeks	10 days	5 days	Anyone experiencing for the first time symptoms that might be related to MS should report them to a healthcare professional within [] of noticing them
ď	4 weeks	10 days	5 days	Anyone who reports symptoms that might be related to MS to a healthcare professional should be referred to a neurologist within []
	4 weeks	2 weeks	5 days	<ul><li>An initial MRI scan should be performed within [] of first referral to a neurologist for diagnosis (if not performed earlier)</li></ul>
	2 months	4 weeks	7 days	■ The MS team should complete a diagnostic workup for MS within [] of referral to a neurologist
	4 weeks	10 days	5 days	The results from a diagnostic workup for MS should be discussed within [] of completion, during an appointment with the patient
	2 months	4 weeks	2 weeks	<ul> <li>An accurate diagnosis of (uncomplicated) MS should be made and communicated to the patient within [] of their referral to a neurologist</li> </ul>
	30 minutes	45 minutes	1 hour	■ Following MS diagnosis, patients should be offered an initial appointment of at least [] to discuss the implications of the diagnosis
Priorities Diagnosis				
following diagnosis	4 weeks	2 weeks	7 days	■ The MS team should discuss the aims of treatment with each patient within [] of MS diagnosis
<b>C</b> 2	6 weeks	3 weeks	7 days	■ The MS team should discuss the pros and cons of early treatment with a DMT with each patient within [] of diagnosis
<b>\</b>	6 weeks	3 weeks	7 days	■ The MS team should assess within [] of an MS diagnosis whether the patient is eligible for treatment with a suitable DMT
So	3 months	4 weeks	10 days	■ The importance of a brain-healthy lifestyle should be discussed with each patient with MS within [] of diagnosis
	6 months	3 months	4 weeks	■ Patients with MS who need additional support to make lifestyle modifications, beyond that offered by the MS team, should be referred to appropriate services within [] of diagnosis
	6 months	-	-	■ Cognitive screening should be offered to all patients with MS within [] of diagnosis
Routine				
monitoring and support	1 year	6 months	-	The MS team should perform a follow-up clinical evaluation of each patient at least once every []
	1 year	6 months	6 months	■ The MS team should review with each patient at least once every [] the aims of their treatment for MS
	1 year	6 months	-	■ The MS team should review at least once every [] whether each patient with MS who is not receiving a DMT is eligible for one, based on applicable guidelines
	1 year	6 months	6 months	The MS team should review with each patient at least once every [] their currently prescribed DMT and consider alternatives if appropriate
	1 year	6 months	-	The MS team should engage patients with MS in an active, documented discussion about living a brain-healthy lifestyle at least once every []
	1 year	6 months	6 months	All patients with MS should have a check-up with an appropriate healthcare professional to screen for and/or manage comorbidities at least once every []
	2 years	1 year	1 year	All patients with MS should be offered an MRI scan at least once every []
Treatment				Patient becomes eligible for DMT
decisions	2 months	3 weeks	10 days	A DMT should be offered to a patient with MS within [] of their becoming eligible for one
1				Patient decides to start DMT
	4 weeks	2 weeks	7 days	Treatment with a DMT should commence within [] of a patient with MS agreeing this approach with their neurologist
	_*	4 weeks	2 weeks	If a patient's response to their current DMT is judged to be suboptimal, an appropriate, alternative DMT should be offered within []
New				New or worsening symptoms
symptoms	2 weeks	7 days	3 days	<ul> <li>Patients with MS should report new or worsened symptoms to their MS team within [] of experiencing these symptoms</li> </ul>
				Reporting new or worsening symptoms
	3 days	2 days	1 day	The MS team should respond within [] to a patient with MS reporting an acute deterioration of symptoms
	7 days	3 days	2 days	■ Patients with MS who experience an acute deterioration of symptoms should be seen by the relevant member of their MS team within [] of reporting these symptoms
Additional				
statements	Aspirational standard: Regular cognitive screening should be offered to all patients with MS			
	Core standard: The MS team should give all patients the opportunity to participate in informed, shared decision-making about their care			

Reproduced from Hobart *et al.* International consensus on quality standards for brain health-focused care in multiple sclerosis. *Mult Scler* 2018; doi:10.1177/1352458518809326. Standards were agreed by at least 75% of the Delphi Consensus Panel. Core, achievable and aspirational grading reflects minimum, good and high standards of MS care, respectively.

Achievable standard: The MS team should regularly enter patient data into an MS database

Core standard: Neurologists should use the latest accepted diagnostic criteria when diagnosing MS

<sup>\*</sup>Time frame of 3 months was agreed by the Delphi Panel after completion of the Delphi process. DMT, disease-modifying therapy; MRI, magnetic resonance imaging; MS, multiple sclerosis.